Integra buys neurosurgical devices firm Arkis Biosciences

31 July 2019 (Last Updated July 31st, 2019 10:36)

Medical technology company Integra LifeSciences has acquired neurosurgical devices maker Arkis Biosciences in a bid to boost its presence in neurocritical care and catheter technology markets.

Integra buys neurosurgical devices firm Arkis Biosciences
The acquisition is intended to expand Integra LifeSciences’ neurocritical care and catheter technology markets. Credit: Pete Linforth from Pixabay.

Medical technology company Integra LifeSciences has acquired neurosurgical devices maker Arkis Biosciences in a bid to boost its presence in neurocritical care and catheter technology markets.

Arkis Biosciences’ portfolio includes the CerebroFlo external ventricular drainage (EVD) catheter featuring Endexo technology, which is a permanent additive intended to decrease catheter obstruction risk due to thrombus formation.

Endexo is claimed to minimise fibrinogen and platelet activation, as well as adhesion in the external ventricular management of cerebrospinal fluid (CSF).

Combination of EVD catheters with EVD systems is used for external CSF drainage in order to address increased ICP in acute brain injury and hydrocephalus patients.

Integra LifeSciences noted that catheter obstruction and bacterial colonisation are two main challenges associated with the external drainage of CSF in neurocritical care patients.

Arkis Biosciences CEO Chad Seaver said: “The introduction of the CerebroFlo EVD Catheter first established the benefits of Endexo in neurocritical care.

“As a world leader in neurosurgery, Integra is the right choice to extend the reach of this important technology to patients and clinicians worldwide.”

Integra LifeSciences expects that the CerebroFlo EVD catheter will complement its Bactiseal Anti-Microbial EVD Catheters meant to reduce gram-positive bacterial colonisation on the catheter surface.

Bactiseal catheters provide protection for up to 28 days after implantation, added the company.

Codman Specialty Surgical president Dan Reuvers said: “Neurocritical care is an important area of focus for Integra. We recently introduced our CereLink Intracranial Pressure Monitor and invested in clinical specialists to better support neurocritical care teams.

“Today’s acquisition expands our leading portfolio to better treat patients and underscores our commitment to addressing unmet needs in-patient care.”

Codman Specialty Surgical is a portfolio of Integra LifeSciences. Financial details of the acquisition have not been disclosed.